Article
Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis.
Frontiers in immunology - 1 Jan 2023
Zhao Yan, Deng Yating, Jiang Yi, Zheng Wenli, Tan Yanlin, Yang Zhiwu, Wang Zhihua, Xu Feng, Cheng Zhao, Yuan Lingli, Peng Hongling
Abstract excerpt
Histiocytic sarcoma (HS) is a rare hematological malignancy with limited treatment options, and it is also prone to complications such as hemophagocytic lymphohistiocytosis (HLH) in the later stages of the disease, leading to difficulties in treatment and poor prognosis. It highlights the importance of developing novel therapeutic agents. Herein, we present a case of a 45-year-old male patient who was diagnosed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
